MarketCapExport financials
Taysha Gene Therapies (TSHA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Taysha Gene Therapies Balance Sheet 2025-2011 | TSHA
Brief overview of Taysha Gene Therapies's balance sheet strength
The comparison uses five available annual reports from the 2021–2025 interval.
The asset base grew from $214 million to $343.3 million, or +60.5%. Average annual growth of roughly 12.5% was strong.
Growth in the asset base was not matched by liabilities: +60.5% versus -18.7%. The balance sheet moved in a more conservative direction.
Equity accounts for 71.9% of assets. Against the initial 44.6%, the capital position looks resilient.
The period ended with net cash: net debt stood at -$268.2 million. This supports financial flexibility.
The cash reserve occupies 93.1% of the balance sheet, previously 69.7%. It is one marker of short-term resilience.
The accumulated result is -$711.3 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Balance sheet takeaway
Taysha Gene Therapies's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Taysha Gene Therapies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-268 M | -93.6 M | -102 M | -48.7 M | -112 M | -251 M | - | - | - | - | - | - | - | - | - |
Long Term Debt |
50.1 M | 43.9 M | 40.5 M | 38 M | 37.2 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.49 M | 1.49 M | 1.29 M | 1.2 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 450 K | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
26.6 M | 26.2 M | 36.8 M | 62.8 M | 51.7 M | 7.13 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
96.4 M | 88.8 M | 97.8 M | 125 M | 119 M | 7.58 M | 150 K | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 9.77 M | 18.1 M | 33.6 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-711 M | -602 M | -513 M | -401 M | -236 M | -61.1 M | -1.12 M | - | - | - | - | - | - | - | - |
Total Assets |
343 M | 160 M | 173 M | 126 M | 214 M | 259 M | 15 K | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
320 M | 139 M | 144 M | 87.9 M | 149 M | 251 M | - | - | - | - | - | - | - | - | - |
Book Value |
247 M | 71.5 M | 74.9 M | 949 K | 95.4 M | 251 M | -135 K | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
247 M | 71.5 M | 74.9 M | 949 K | 95.4 M | 251 M | -135 K | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Taysha Gene Therapies
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
18.2 M | 49 M | 17.4 M | 50.9 M | 41.1 M | 42.5 M | 43.9 M | 43 M | 37.8 M | 40.5 M | 40.5 M | 38.5 M | 38.4 M | 38.2 M | 38 M | 37.8 M | 37.6 M | 37.4 M | 37.2 M | 27.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
96.4 M | 88.4 M | 88.8 M | 97.6 M | 84.6 M | 83.3 M | 88.8 M | 91.4 M | 91.5 M | 99.2 M | 97.8 M | 245 M | 119 M | 117 M | 125 M | 100 M | 110 M | 115 M | 119 M | 101 M | 55.4 M | 20 M | 7.58 M | 7.58 M | 7.58 M | 7.58 M | 150 K | 150 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 9.77 M | 5.48 M | 5.48 M | 7.47 M | 9.77 M | 11.8 M | 13.6 M | 14.7 M | 18.1 M | 18.8 M | 20.2 M | 28.9 M | 33.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-711 M | -754 M | -602 M | -683 M | -651 M | -624 M | -602 M | -584 M | -558 M | -537 M | -513 M | -561 M | -444 M | -419 M | -401 M | -346 M | -320 M | -286 M | -236 M | -185 M | -134 M | -93.2 M | -61.1 M | -61.1 M | -61.1 M | -61.1 M | -1.12 M | -1.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
343 M | 300 M | 160 M | 317 M | 333 M | 138 M | 160 M | 180 M | 200 M | 153 M | 173 M | 196 M | 81.5 M | 102 M | 126 M | 111 M | 142 M | 166 M | 214 M | 241 M | 242 M | 243 M | 259 M | 259 M | 259 M | 259 M | 15 K | 15 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
313 M | 277 M | 139 M | 297 M | 313 M | 117 M | 139 M | 158 M | 173 M | 124 M | 144 M | 164 M | 45.1 M | 63.4 M | 87.9 M | 34.3 M | 66.2 M | 96.6 M | 149 M | 189 M | 197 M | 229 M | 251 M | 251 M | 251 M | 251 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
247 M | 212 M | 71.5 M | 219 M | 249 M | 55.1 M | 71.5 M | 88.8 M | 109 M | 53.8 M | 74.9 M | -49.1 M | -37.1 M | -14.9 M | 949 K | 11.1 M | 32.7 M | 50.7 M | 95.4 M | 140 M | 186 M | 223 M | 251 M | 251 M | 251 M | 251 M | -135 K | -135 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
71.5 M | 212 M | 74.9 M | 219 M | 249 M | 55.1 M | 71.5 M | 88.8 M | 109 M | 53.8 M | 74.9 M | -49.1 M | -37.1 M | -14.9 M | 949 K | 10.7 M | 32.5 M | 50.7 M | 95.4 M | 140 M | 186 M | 223 M | 251 M | 251 M | 251 M | 251 M | -135 K | -135 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Taysha Gene Therapies, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Trevi Therapeutics
TRVI
|
$ 12.77 | -0.47 % | $ 1.72 B |  USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.2 | -9.61 % | $ 9.14 M |  Israel |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | USA |
 |
Innoviva
INVA
|
$ 20.91 | -1.74 % | $ 1.41 B | USA |
 |
Genmab A/S
GMAB
|
$ 39.57 | 1.28 % | $ 2.56 B |  Danmark |
 |
UroGen Pharma Ltd.
URGN
|
$ 35.48 | 1.34 % | $ 1.71 B | Israel |
 |
United Therapeutics Corporation
UTHR
|
$ 563.49 | 1.74 % | $ 25 B | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.4 | -5.27 % | $ 4.43 M | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | USA |
 |
Vericel Corporation
VCEL
|
$ 40.94 | 0.89 % | $ 2.06 B | USA |
 |
Veracyte
VCYT
|
$ 46.22 | 3.19 % | $ 3.63 B | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 3.55 | -2.2 % | $ 575 M | USA |
 |
Vir Biotechnology
VIR
|
$ 10.57 | -1.58 % | $ 1.46 B | USA |
 |
Viking Therapeutics
VKTX
|
$ 26.38 | -1.24 % | $ 2.97 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
$ 4.01 | -3.84 % | $ 236 M | USA |
 |
Johnson & Johnson
JNJ
|
$ 257.78 | -0.6 % | $ 621 B | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.63 | 4.61 % | $ 38.7 M | USA |
 |
Viridian Therapeutics
VRDN
|
$ 23.01 | 2.59 % | $ 2.34 B | USA |
 |
Verastem
VSTM
|
$ 9.21 | -1.39 % | $ 638 M | USA |
 |
VistaGen Therapeutics
VTGN
|
$ 0.19 | -2.12 % | $ 7.23 M | USA |
 |
vTv Therapeutics
VTVT
|
$ 27.77 | -0.27 % | $ 110 M | USA |
 |
Genprex
GNPX
|
$ 2.05 | -3.76 % | $ 1.91 M | USA |
 |
Voyager Therapeutics
VYGR
|
$ 2.02 | -7.76 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 6.4 | -0.31 % | $ 190 M | USA |
 |
Halozyme Therapeutics
HALO
|
$ 124.83 | 0.37 % | $ 15 B | USA |
 |
Kura Oncology
KURA
|
$ 9.88 | -1.0 % | $ 866 M | USA |
 |
Arvinas
ARVN
|
$ 7.56 | -1.37 % | $ 536 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.62 | -2.41 % | $ 431 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
$ 67.74 | 0.28 % | $ 13 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
$ 38.31 | -1.01 % | $ 2.2 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 8.18 | 3.81 % | $ 125 M |  Australia |
 |
CNS Pharmaceuticals
CNSP
|
$ 4.83 | -3.31 % | $ 2.14 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | USA |
 |
MacroGenics
MGNX
|
$ 3.59 | 2.87 % | $ 227 M | USA |
 |
iBio
IBIO
|
$ 0.84 | 2.31 % | $ 87.4 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 62.86 | -1.7 % | $ 7.55 M | USA |
 |
Immunome
IMNM
|
$ 18.0 | 0.45 % | $ 1.57 B | USA |
 |
Immuron Limited
IMRN
|
$ 0.97 | -4.9 % | $ 224 M | Australia |
 |
Moderna
MRNA
|
$ 245.81 | 1.54 % | $ 95.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.36 | 1.49 % | $ 5.66 M |  Canada |
 |
INmune Bio
INMB
|
$ 1.61 | 0.62 % | $ 39.9 M | USA |
 |
Novo Nordisk A/S
NVO
|
$ 39.06 | -0.71 % | $ 174 B | Danmark |
 |
Inovio Pharmaceuticals
INO
|
$ 0.8 | -21.26 % | $ 37.5 M | USA |
 |
Insmed Incorporated
INSM
|
$ 94.04 | -1.7 % | $ 18.7 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.75 | -0.51 % | $ 760 M | USA |
 |
Biogen
BIIB
|
$ 240.98 | -0.87 % | $ 35.3 B | USA |
 |
BioVie
BIVI
|
$ 1.26 | 1.61 % | $ 1.86 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 44.27 | -2.49 % | $ 7.08 B | USA |